Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies: Table 1

Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force

(2016) Cindy Strehl et al.   ANNALS OF THE RHEUMATIC DISEASES

Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis

(2013) Marije F. Bakker   ANNALS OF INTERNAL MEDICINE

EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases

(2013) N Duru et al.   ANNALS OF THE RHEUMATIC DISEASES

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab

(2013) Joachim Listing et al.   ANNALS OF THE RHEUMATIC DISEASES

Glucocorticoid Dose Thresholds Associated With All-Cause and Cardiovascular Mortality in Rheumatoid Arthritis

(2013) Inmaculada del Rincón et al.   Arthritis & Rheumatology

American College of Rheumatology treatment guidelines continue to omit guidance on glucocorticoids: Comment on the article by Singh et al

(2012) Maarten Boers et al.   ARTHRITIS CARE & RESEARCH

Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis?

(2011) F. Buttgereit   ANNALS OF THE RHEUMATIC DISEASES